| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SGC-CBP30 is a novel, potent and selective inhibitor of CREBBP (CBP/KAT3A) and its paralogue EP300 (KAT3B) with the potential to be used in neurodegenerative diseases (e.g. Alzheimer's disease). CREBBP/EP300 are the lysine acetyltransferases (KATs) that are essential for human development. It inhibits CREBBP and EP300 bromodomains with IC50s of 21 nM and 38 nM in cell-free assays, respectively. CREBBP (CBP) and EP300 are general transcriptional co-activators. CREBBP has also been associated with Amyotrophic Lateral Sclerosis (ALS) or Lou GehrigÂ’s disease, a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and poly glutamine repeat diseases such as Spinal and Bulbar Muscular Atrophy and HuntingtonÂ's disease.
| ln Vitro |
In ankylosing spondylitis and psoriatic arthritis situations, SGC-CBP30 suppresses IL-17A release by Th17 cells. Transcriptional profiling of human T cells following SGC-CBP30 treatment demonstrated more restricted effects on gene expression than that reported with the pan-BET (bromodomain and ecto-terminal protein family) bromodomain inhibitor JQ1[1] .
|
|---|---|
| ln Vivo |
Treatment with SGC-CBP30 somewhat reduced the alveolar bronchial fibrosis caused by NSC-125066. Alveolar bronchial fibrosis is greatly reduced by SGC-CBP30 with CQ-061. The combination of SGC-CBP30 0 and CQ-061 suppressed the activation of IL-4 and IFN-γ in the NSC-125066-induced IPF mouse model to near normal levels, according to an ELISA of the cytokines IL-4 and IFN-γ in BALF [2].
|
| Animal Protocol |
Animal/Disease Models: SD (Sprague-Dawley) rats (aged 3-4 weeks) injected with NSC-125066[2]
Doses: 25 mg/kg Route of Administration: Oral administration; daily; for 14 days Experimental Results: Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066. |
| References |
|
| Molecular Formula |
C28H33CLN4O3
|
|
|---|---|---|
| Molecular Weight |
509.04
|
|
| Exact Mass |
508.224
|
|
| CAS # |
1613695-14-9
|
|
| Related CAS # |
|
|
| PubChem CID |
72201027
|
|
| Appearance |
Off-white to yellow solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
678.0±55.0 °C at 760 mmHg
|
|
| Flash Point |
363.8±31.5 °C
|
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
|
| Index of Refraction |
1.629
|
|
| LogP |
5.29
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
36
|
|
| Complexity |
698
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
CC1=C(C(=NO1)C)C2=CC3=C(C=C2)N(C(=N3)CCC4=CC(=C(C=C4)OC)Cl)C[C@H](C)N5CCOCC5
|
|
| InChi Key |
GEPYBHCJBORHCE-SFHVURJKSA-N
|
|
| InChi Code |
InChI=1S/C28H33ClN4O3/c1-18(32-11-13-35-14-12-32)17-33-25-8-7-22(28-19(2)31-36-20(28)3)16-24(25)30-27(33)10-6-21-5-9-26(34-4)23(29)15-21/h5,7-9,15-16,18H,6,10-14,17H2,1-4H3/t18-/m0/s1
|
|
| Chemical Name |
(S)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propan-2-yl)morpholine
|
|
| Synonyms |
SGC-CBP 30; SGC-CBP-30; SGC-CBP30.
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O:5 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9645 mL | 9.8224 mL | 19.6448 mL | |
| 5 mM | 0.3929 mL | 1.9645 mL | 3.9290 mL | |
| 10 mM | 0.1964 mL | 0.9822 mL | 1.9645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA